Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Penny J Barnes"'
Publikováno v:
Canadian Respiratory Journal, Vol 7, Iss 6, Pp 491-495 (2000)
Hydroxyurea is a cytotoxic agent indicated in the treatment of a variety of malignant and nonmalignant conditions. Apart from dose-related bone marrow suppression, this antineoplastic agent is generally well tolerated. This report describes a patient
Externí odkaz:
https://doaj.org/article/6022519af3814eb695fbd714d28cc450
Publikováno v:
Virchows Archiv. 479:23-31
In 2018, the American Society of Clinical Oncology/College of American Pathologists revised the criteria for HER2 immunohistochemistry (IHC) equivocal (2+) classification in their updated guideline. We reviewed invasive breast cancer specimens origin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b54df218ce5bfa53cbf2bda2276539cd
https://doi.org/10.1007/s00428-021-03034-4
https://doi.org/10.1007/s00428-021-03034-4
Publikováno v:
Applied immunohistochemistrymolecular morphology : AIMM. 30(10)
Invasive breast carcinomas are routinely tested for HER2 using immunohistochemistry (IHC), with reflex in situ hybridization (ISH) for those scored as equivocal (2+). ISH testing is expensive, time-consuming, and not universally available. In this st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::052dfd89f58d38127e9ddbf13575f1d7
https://pubmed.ncbi.nlm.nih.gov/36251973
https://pubmed.ncbi.nlm.nih.gov/36251973
Autor:
Jennifer Payne, Michael Rivers-Bowerman, Olivia Tong, Sian Iles, Pam Talbot, Judy S Caines, Mohamed Abdolell, Kaitlyn Tsuruda, Peter Brown, Penny J. Barnes
Publikováno v:
European Radiology. 30:5417-5426
To develop a breast cancer risk model to identify women at mammographic screening who are at higher risk of breast cancer within the general screening population. This retrospective nested case-control study used data from a population-based breast s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::752827e876f91044df12a9d6b2c6a45c
https://doi.org/10.1007/s00330-020-06901-x
https://doi.org/10.1007/s00330-020-06901-x
Metastatic Mammary Carcinoma Presenting as a Large Cystic Axillary Mass: A Report of an Unusual Case
Publikováno v:
International Journal of Surgical Pathology. :106689692311525
The differential diagnosis of cystic axillary masses is broad and includes intranodal lesions. Cystic metastatic tumor deposits are rare, and have been reported in a few tumor types, most commonly in the head and neck region, but rarely described wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::50e2032d9d8eff5cc4593f97ae665cdb
https://doi.org/10.1177/10668969231152574
https://doi.org/10.1177/10668969231152574
Publikováno v:
American Journal of Clinical Pathology. 156:S27-S28
Introduction/Objective Current guidelines recommend HER2 testing on all primary invasive breast cancers and at least one metastatic lesion. Typical HER2 testing involves immunohistochemistry (IHC), with reflex in situ hybridization (ISH) in the event
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20d23de1d6308b521567d24d41a720b8
https://doi.org/10.1093/ajcp/aqab191.053
https://doi.org/10.1093/ajcp/aqab191.053
Publikováno v:
Virchows Archiv : an international journal of pathology. 479(1)
In 2018, the American Society of Clinical Oncology/College of American Pathologists revised the criteria for HER2 immunohistochemistry (IHC) equivocal (2+) classification in their updated guideline. We reviewed invasive breast cancer specimens origin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0d06df6357bf1c2ba029111cc47b0f9c
https://pubmed.ncbi.nlm.nih.gov/33527151
https://pubmed.ncbi.nlm.nih.gov/33527151
Publikováno v:
HistopathologyReferences. 77(5)
Cystic neutrophilic granulomatous mastitis (CNGM) is an uncommon but increasingly recognised cause of mastitis, often associated with Corynebacterium ssp. infection. We studied the histopathological and clinical features of CNGM in a Canadian setting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8aaf7af6bddde04df073b8646b5290d7
https://pubmed.ncbi.nlm.nih.gov/32557756
https://pubmed.ncbi.nlm.nih.gov/32557756
Autor:
Gilad W. Vainer, H. Wang, Julien Adam, Catherine L. Ross, Ka F. To, Gilbert Bigras, Diana N. Ionescu, Ming-Sound Tsao, Paul E. Swanson, Chao Li, Anthony W.H. Chan, Jin Haeng Chung, Zhaolin Xu, Katsuhiro Okuda, Marianne Ratcliffe, Rasmus Røge, Maria S. Tretiakova, Andreas H. Scheel, Marius Ilie, Hyun J. Lim, Gang Han, Daichi Fujimoto, Enrico Munari, Dirk Zielinski, Emina Torlakovic, Fred R. Hirsch, Penny J. Barnes, David L. Rimm, Ross A. Soo, Pierre Fiset, Christian Couture, Carol C Cheung
Publikováno v:
Torlakovic, E, Lim, H J, Adam, J, Barnes, P, Bigras, G, Chan, A W H, Cheung, C C, Chung, J-H, Couture, C, Fiset, P O, Fujimoto, D, Han, G, Hirsch, F R, Ilie, M, Ionescu, D, Li, C, Munari, E, Okuda, K, Ratcliffe, M J, Rimm, D L, Ross, C, Røge, R, Scheel, A H, Soo, R A, Swanson, P E, Tretiakova, M, To, K F, Vainer, G W, Wang, H, Xu, Z, Zielinski, D & Tsao, M-S 2020, ' "Interchangeability" of PD-L1 immunohistochemistry assays : a meta-analysis of diagnostic accuracy ', Modern Pathology, vol. 33, no. 1, pp. 4-17 . https://doi.org/10.1038/s41379-019-0327-4
Modern Pathology
Modern Pathology
Different clones, protocol conditions, instruments, and scoring/readout methods may pose challenges in introducing different PD-L1 assays for immunotherapy. The diagnostic accuracy of using different PD-L1 assays interchangeably for various purposes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad64999e64af73e6d8c2a5bc82d73cdf
https://vbn.aau.dk/ws/files/320397307/Torlakovic_et_al_2020_Interchangeability_of_PD_L1_immunohistochemistry_assays.pdf
https://vbn.aau.dk/ws/files/320397307/Torlakovic_et_al_2020_Interchangeability_of_PD_L1_immunohistochemistry_assays.pdf
Autor:
Jagdish Butany, Fiorella Calabrese, Zhaolin Xu, Hyun J. Lim, Pierre Fiset, Adnan Mansoor, Victor A Tron, Emina Torlakovic, Scott L. Boerner, Christian Couture, Hala El-Zimaity, Penny J. Barnes, Gabor Fischer, John Garratt, Sinchita Roy-Chowdhuri, C. Blake Gilks, Lisa Manning, Laurette Geldenhuys, Carol C Cheung, Gilbert Bigras, H. Wang, Catherine Ross, Marius Ilie, Jean Deschenes, Alan Spatz, Robert H. Riddell, Ming-Sound Tsao, Paul E. Swanson, Diana N. Ionescu
Publikováno v:
Applied Immunohistochemistry & Molecular Morphology
Supplemental Digital Content is available in the text.
Since 2014, programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) checkpoint inhibitors have been approved by various regulatory agencies for the treatment of multipl
Since 2014, programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) checkpoint inhibitors have been approved by various regulatory agencies for the treatment of multipl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f3ee6a8d99853b79b889b03a84bac02
https://pubmed.ncbi.nlm.nih.gov/32282341
https://pubmed.ncbi.nlm.nih.gov/32282341